atorvastatin has been researched along with Hypertension in 258 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.39) | 18.2507 |
| 2000's | 124 (48.06) | 29.6817 |
| 2010's | 112 (43.41) | 24.3611 |
| 2020's | 21 (8.14) | 2.80 |
| Authors | Studies |
|---|---|
| Teoh, CS; Yuen, YS | 1 |
| Al-Mohammadi, OS; Al-Qaaneh, AM; Mustafa, SM; Obaid, WT; Rabaan, AA | 1 |
| Borghi, C; Levy, BI | 1 |
| Godec, T; Gupta, A; Norling, LV; Oggero, S; Perretti, M; Pinto, AL; Reutelingsperger, C; Schurgers, LJ; Sever, P; van Gorp, R | 1 |
| Borghi, C; Cicero, AFG; D'Addato, S; Fogacci, F; Giovannini, M; Rizzoli, E | 1 |
| Li, X; Yang, Q; Yang, Y | 1 |
| Banerjee, S; Biswas, S; Chanda, J; Kar, A; Mukherjee, PK; Tiwari, A; Ulrich-Merzenich, G | 1 |
| Belo, VS; Chaves, VE; Costa, GS; de Oliveira, HCF; Julião-Silva, LS | 1 |
| Qiu, Y; Yang, G | 1 |
| Dong, B; Dong, S; Li, L; Liu, Q; Shen, J; Yang, K; Zhao, Y; Zhou, X; Zhu, D | 1 |
| Chen, K; Lan, S; Liao, G; Luo, H; Xie, Z; Xu, J; Xu, S; Yang, X | 1 |
| Cao, L; Huang, X; Li, D; Liu, J; Lu, S; Sun, Y; Wu, B; Yin, Z; You, S; Zhang, L; Zhang, N; Zhang, S; Zhang, X; Zhang, Y | 1 |
| Bae, HJ; Cho, EJ; Choi, JY; Han, KR; Hong, BK; Hong, SP; Hyon, MS; Jin, HY; Jung, HW; Kim, CY; Kim, KS; Kim, SY; Kim, U; Lee, JB; Lee, KH; Lee, KJ; Lee, SR; Lee, SY; Nam, CW; Park, CG; Park, SJ; Park, TH; Rhee, MY; Ryu, JK; Seol, SH; Shin, JH; Yang, DH; Yu, GW | 1 |
| Du, M; Wang, Q; Wang, T; Zhu, S | 1 |
| Namazova, GA; Shupenina, EY; Vasyuk, YA; Zavyalova, AI | 1 |
| Tao, J | 1 |
| Degli Esposti, L; Gambera, M; Nati, G; Perone, F; Perrone, V; Tagliabue, PF; Veronesi, C; Volpe, M | 1 |
| Blot, WJ; Gonzales, H; Miller, R; Muñoz, D; Munro, H; Pappalardo, S; Reynolds, C; Song, W; Tousey, P; Uzoije, P; Walkley, D; Wang, TJ; White, C | 1 |
| Tůmová, E; Vrablík, M | 1 |
| Chu, PH; Chu, YC; Hsiao, FC; Kao, YW; Lin, CP; Lin, YS; Tung, YC; Yang, CH | 1 |
| Zlatohlávek, L | 1 |
| Ancion, A; Lancellotti, P; Scheen, AJ | 1 |
| Chan, JYW; Cheung, DWS; Fung, KP; Ko, ECH; Koon, JCM; Lau, VKM; Wat, ECL; Waye, MMY; Wong, PH; Yau, KC | 1 |
| Godec, T; Gupta, AK; Mackay, J; Rostamian, S; Sever, PS; Whitehouse, A; Whiteley, WN | 1 |
| Bonsu, KO; Buabeng, KO; Kadirvelu, A; Owusu, IK; Reidpath, DD | 1 |
| Collier, T; Collins, R; Dahlof, B; Gupta, A; Poulter, N; Sever, P; Thompson, D; Whitehouse, A | 1 |
| Li, K; Li, T; Zhai, S; Zhang, K; Zhang, Z | 1 |
| Radermecker, RP | 1 |
| Bartlett, LE; Pratt, N; Roughead, EE | 1 |
| Anil, C; Bozkus, Y; Demir, C; Kut, A; Mousa, U; Nar, A; Tutuncu, NB | 1 |
| Agrawal, Y; Kalavakunta, JK; Zoltowska, DM | 1 |
| Guo, Y; Wang, H; Yin, J | 1 |
| Chang, Y; Chen, Y; Guo, X; Sun, G; Sun, Y; Zhang, N | 1 |
| Akbari, H; Asadikaram, G; Ebrahimi, G; Ebrahimi, N; Jafari, A; Masoumi, M; Nazari-Robati, M | 1 |
| Brackett, CD; Ornstein, DL; Strait, AM | 1 |
| Collier, T; Godec, T; Gupta, A; Mackay, J; Pocock, S; Poulter, N; Sever, P; Whitehouse, A | 1 |
| Liu, Y; Shao, Y; Tao, J; Zhang, J | 1 |
| Chang, L; Song, L; Wang, H; Zou, G | 1 |
| Jonnalagadda, VG | 1 |
| Cheng, Q; Liu, Y; Wang, X; Yang, G; Zhao, J | 1 |
| Psaradellis, E; Rampakakis, E; Rickard, J; Sampalis, JS; Stutz, M | 1 |
| Akbari, H; Asadikaram, G; Masoumi, M; Vakili, S | 1 |
| Christopher-Stine, L; Isackson, PJ; Kitzmiller, JP; Luzum, JA; Ma, C; Nguyen, LM; Ochs-Balcom, HM; Peltier, W; Tarnopolsky, M; Vladutiu, GD; Weisman, M; Wortmann, RL | 1 |
| Fang, T; Guo, B; Wang, L; Xue, L | 1 |
| Finsterer, J; Stollberger, C | 1 |
| Ihm, SH; Kim, CH; Park, CG; Shin, J | 1 |
| Beleford, DT; Diab, M; Long, RK; Malloy, MJ; Qubty, WF; Shieh, JT | 1 |
| Dézsi, CA; Simon, A | 1 |
| Ahsan, MZ; Bai, B; Han, X; Li, Y; Liu, G; Yuan, Y; Zhang, J; Zhang, S; Zhang, Y; Zhao, X | 1 |
| Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y | 1 |
| Georgianos, PI; Kanaki, AI; Kanavos, K; Lasaridis, AN; Sarafidis, PA; Tziolas, IM; Zebekakis, PE | 1 |
| Hradec, J; Sutradhar, S; Zamorano, J | 1 |
| Amini, R; Jahanbakhsh, Z; Mohammadi, MT; Shekarforoush, S | 1 |
| Andersson, O; Bergh, N; Grote, L; Hrafnkelsdóttir, TJ; Saluveer, O; Widgren, BR | 1 |
| Chang, CL; Hughes, AD; Poulter, NR; Sattar, N; Sever, PS; Thom, SA; Welsh, P | 1 |
| Bangalore, S; Deedwania, P; DeMicco, D; Fayyad, R; Kostis, JB; Laskey, R; Messerli, FH | 1 |
| Arican, N; Gelisgen, R; Kalayci, R; Kaya, M; Konukoglu, D; Sozer, V; Tabak, O; Uzun, H | 1 |
| Guo, F; Han, W; Li, JX; Li, YD; Tang, BP; Tang, Q; Zhang, YY | 1 |
| Chen, JW; Chen, JY; Chien, KL; Hsia, CH; Hung, YR; Lin, HJ; Lin, LY; Liu, PY; Wu, TC; Yeh, HI | 1 |
| Takagi, H; Umemoto, T | 1 |
| Aksoy, Y; Senen, K; Sivri, N; Tekin, G; Yalta, K; Yetkin, E | 1 |
| Bangalore, S; Deedwania, P; Demicco, DA; Fayyad, R; Kostis, JB; Laskey, R; Messerli, FH | 1 |
| Jaimes, EA; Raij, L; Tian, R; Zhou, MS | 1 |
| Chattopadhyay, S; Dey, S; Mazumder, B | 1 |
| Cong, H; Fu, N; Jin, D; Li, H; Li, X; Ma, H; Wang, Y | 1 |
| Akahori, H; Eguchi, A; Hirotani, S; Iwasaku, T; Masuyama, T; Matsumoto, M; Naito, Y; Sasaki, N; Sawada, H; Tsujino, T | 1 |
| Azushima, K; Dejima, T; Kanaoka, T; Kobayashi, R; Maeda, A; Ohsawa, M; Tamura, K; Toya, Y; Umemura, S; Uneda, K; Wakui, H | 1 |
| Chen, W; Gao, DC; Ye, PX; Ye, PZ; Zhu, JH | 1 |
| de Ceuninck, M; Trenson, S | 1 |
| Kartashova, EA; Romantsov, MG; Sarvilina, IV | 1 |
| O'Brien, E | 1 |
| Choudhury, S; Gupta, P; Harikumar, SK; Kannan, K; Mishra, SK; Pillai, AH; Sarath, TS; Sarkar, SN; Waghe, P | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 1 |
| Bespalova, ID; Kaliuzhin, VV; Mediantsev, IuA; Murashev, BIu; Osikhov, IA; Riazantseva, NV | 2 |
| Berg, AH; Drechsler, C; Hod, T; Kalim, S; Karumanchi, SA; Suntharalingam, P; Thadhani, RI; Wanner, C; Wenger, JB | 1 |
| Corbalan, JJ; Dawoud, H; Jacob, RF; Malinski, T; Mason, RP | 1 |
| Bochar, OM | 1 |
| AlBacha, Jd; Azar, A; Fajloun, Z; Haddad, K; Hamoui, S; Khoury, M; Makdissy, N; Mouawad, C | 1 |
| Breazna, A; Deedwania, PC; DeMicco, DA; Shepherd, J | 1 |
| Chang, YH; Chien, LN; Chuang, MT; Lin, CF; Liu, JC | 1 |
| Cui, W; Du, H; Hao, J; Liu, D; Liu, F; Lu, J; Yang, X | 1 |
| Ferenci, T; Simonyi, G | 1 |
| Celovska, D; Delev, D; Dukat, A; Gaspar, L; Gaspar, P; Gonsorcik, J; Kruzliak, P; Petrovic, D; Rodrigo, L; Sabaka, P | 1 |
| Boekholdt, SM; Colhoun, HM; Davis, BR; Kaasenbrood, L; Livingstone, SJ; Poulter, NR; Pressel, SL; Sever, PS; van der Graaf, Y; Visseren, FL | 1 |
| Cui, W; Du, H; Hao, J; Li, Y; Lu, J; Xiao, B; Yang, X | 1 |
| Chang, YY; Hung, CS; Kao, HL; Lee, JK; Lin, HJ; Lin, YH; Lin, YM; Lin, YT; Wu, YW | 1 |
| Wang, M; Zeng, R; Zhang, L | 1 |
| Chae, SC; Cho, DG; Chung, MH; Ha, JW; Han, GR; Hyon, MS; Jo, SH; Kim, CH; Kim, DW; Kim, KS; Kim, SH; Kim, YD; Lee, HL; Lee, NH; Lee, SC; Lee, SY; Oh, BH; Park, CG; Ryu, GH; Seung, KB; Yoon, MH | 1 |
| Bangalore, S; DeMicco, DA; Fayyad, R; Kastelein, JJ; Laskey, R; Messerli, FH; Waters, DD | 1 |
| Asadikaram, G; Ebrahimi, N; Kazemi Arababadi, M; Kiani, Z; Kohan, F; Masoumi, M; Nasiri, AA; Sepehri, Z; Sheikh Fathollahi, M | 1 |
| Deedwania, P; Singh, V | 1 |
| Amarenco, P; Callahan, A; Gilbert, S; Goldstein, LB; Hennerici, M; Lamonte, M; Messig, M; Sillesen, H; Welch, KM | 1 |
| Mehlsen, J | 1 |
| Aguilar-Salinas, CA; Chaves, H; Chopra, P; Erdine, S; Guindy, R; Howes, LG; Moller, RA; Ro, YM; Schou, IM; Tse, HF | 1 |
| Kékes, E | 1 |
| Foody, JM; Honda, D; Leslie, RS; Nichol, MB; Patel, BV; Solomon, H; Tang, SS; Thiebaud, P | 1 |
| Chen, GP; Hu, SJ; Lu, X; Mou, Y; Yao, L; Zheng, LR | 1 |
| Chen, X; Liu, C; Peng, W; Qi, B; Wan, J; Yang, Q | 1 |
| Coimbra, SR; Crisostomo, LM; Favarato, D; Luz, PL; Mendes, CM; Souza, CA | 1 |
| Zuber, M | 1 |
| Blanco-Colio, LM; Egido, J; Madrigal-Matute, J; Martín-Conejero, A; Martín-Ventura, JL; Muñoz-Garcia, B; Ortega, L; Serrano, J; Vega, M | 1 |
| Cohn, JN; Grimm, R; Houston, M; Neutel, J; Smith, DH; Sun, W; Weinberger, MH; Wilson, DJ | 1 |
| Fujii, T; Kunita, E; Maeda, K; Sekiguchi, Y; Tasaki, N; Tsujiyama, S; Urabe, Y | 1 |
| Collier, D; Cruickshank, JK; Hughes, AD; Lacy, PS; Stanton, A; Thom, S; Thurston, H; Williams, B | 1 |
| Hanhart, J; Koskas, P; Le Mer, Y; Obadia, M; Paques, M; Sahel, JA | 1 |
| Bestermann, WH; Dyess, EM; Graff, A; Kursun, A; Neutel, JM; Sutradhar, S; Yunis, C | 1 |
| Chang, CL; Dahlof, B; Mastorantonakis, S; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Chen, Y; Cheng, X; Ding, Y; Liao, M; Liao, YH; Tang, T; Wang, M; Xia, C; Xie, J; Yao, R; Yu, X | 1 |
| Dahlof, B; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H | 2 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Bauer, B; da Silva, PM; Feldman, RD; Genest, J; Gensini, G; Harvey, P; Jenssen, TG; John Mancini, GB; Manolis, AJ; Richard Hobbs, FD | 1 |
| Bangalore, S; Devabhaktuni, M | 1 |
| Brocheriou, I; Capron, F; Dupuis, M; Haloui, M; Louedec, L; Michel, JB; Nadaud, S; Soubrier, F | 1 |
| Abramczyk, P; Bidiuk, J; Ciarka, A; Dobosiewicz, A; Gaciong, Z; Lewandowski, J; Siński, M | 1 |
| Han, SH; Kim, SJ; Koh, KK; Koh, Y; Lee, Y; Park, JB; Quon, MJ; Shin, EK | 1 |
| Geng, J; Kang, W; Wang, W; Zhang, Y; Zhao, Z; Zhiming, GE | 1 |
| Hughes, AD; Manisty, C; Mayet, J; McG Thom, SA; Poulter, N; Sever, PS; Tapp, RJ | 1 |
| He, CC; He, WK; Liang, LY; Luo, BH; Su, CJ; Zeng, ZH; Zhang, ZH | 1 |
| Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K | 1 |
| Raczak, G | 1 |
| Cui, W; Ibi, M; Ikami, K; Iwata, K; Kakehi, T; Katsuyama, M; Matsuno, K; Sasaki, M; Yabe-Nishimura, C; Zhu, K | 1 |
| Hirooka, Y; Kishi, T; Konno, S; Sunagawa, K | 2 |
| Kaminski, K; Knapp, M; Kozieradzka, A; Kuklinska, AM; Mroczko, B; Musial, WJ; Sawicki, R; Szmitkowski, M; Usowicz-Szarynska, M | 1 |
| Al Khadra, A; Erdine, S; Kim, JH; Lopez, AP; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J | 1 |
| Tasci, I | 1 |
| Benner, JS; Chapman, RH; Foody, JM; Hussein, MA; Joyce, A; Solomon, HA; Tang, SS | 1 |
| Eckel, RH | 1 |
| Perlamutrov, IuN; Shkol'nik, EL; Shkol'nik, MN; Vasiuk, IuA | 1 |
| Foody, JM; Liu, LZ; Mendys, PM; Simpson, RJ | 1 |
| Beckerman, B; Buch, J; Bultas, J; Deanfield, JE; Sellier, P; Shi, H; Thaulow, E; Yunis, C | 1 |
| Buxton, M; Dahlöf, B; Eriksson, J; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Derosa, G; Maffioli, P | 1 |
| Chen, L; Eaddy, M; Jackson, JH; Kean, AJ; Lunacsek, OE; Neutel, JM; Roberts, C | 1 |
| Funder, JW | 1 |
| Lopatin, IuM | 1 |
| Acharjee, S; Cannon, CP | 1 |
| Abrashkina, ED; Nazarova, OA; Pakhrova, OA; Shaalali, N; Shutemova, EA | 1 |
| Bangalore, S; DeMicco, D; Kostis, JB; LaRosa, JC; Messerli, FH; Wun, CC; Zuckerman, AL | 1 |
| Gomes, ME; Lenders, JW; Smits, P; Tack, CJ; Verheugt, FW | 1 |
| Bangalore, S; Cannon, CP; Murphy, SA; Qin, J; Sloan, S | 1 |
| Hirooka, Y; Kishi, T | 1 |
| Hu, SJ; Kang, L | 2 |
| Buch, J; Caulfield, MJ; Collier, DJ; Dahlöf, B; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Al-Khadra, A; Erdine, S; Kim, JH; Pavia, A; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J | 1 |
| Campo, N; Campo-Bustillo, I; Forteza, A; Gutierrez, J; Haussen, DC; Koch, S; Romano, JG | 1 |
| Ferreira-Sae, MC; Franchini, KG; Geloneze, B; Grespan-Magossi, AM; Nadruz, W; Pio-Magalhães, JA; Schreiber, R; Souza, FA; Velloso, LA | 1 |
| Caulfield, M; Chang, CL; Chapman, N; Dahlöf, B; Feder, G; Poulter, NR; Sever, PS | 1 |
| Chang, CL; Hingorani, A; Hughes, AD; Poulter, NR; Sattar, N; Sever, PS; Thom, SA; Welsh, P | 1 |
| Crabbe, A; Delkhah, Y; Jones, J; Leonard, D; Nesbitt, S; Oliver, S | 1 |
| De Backer, GG | 1 |
| Chang, CL; Gupta, AK; Poulter, NR; Sever, PS; Whitehouse, A | 1 |
| Georgianos, PI; Kanaki, AI; Kanavos, K; Lasaridis, AN; Sarafidis, PA; Stafylas, PC; Tziolas, IM | 1 |
| Anderson, L; Bhattacharya, S; Bose, N; Fraser, E; Graham, K; Lumsden, G; McClue, L; Robertson, L; Tho, LM; Yosef, H | 1 |
| Betteridge, DJ; Calle, RA; Caulfield, M; Charlton-Menys, V; Chatterjee, A; Colhoun, HM; DeMicco, DA; Deshmukh, HA; Durrington, PN; Ford, I; Fuller, JH; Hitman, GA; Hyde, C; Johnson, T; Jukema, JW; Livingstone, S; McKeigue, PM; Neil, A; Postmus, I; Poulter, N; Sever, P; Shields, DC; Stanton, AV; Trompet, S | 1 |
| Guo, Y; Wang, J; Xu, D; Xu, J; Yang, Z; Zhang, Y; Zhou, C | 1 |
| Arsenault, BJ; Boekholdt, SM; Breazna, A; Deedwania, P; Demicco, DA; Kastelein, JJ; Mora, S; Waters, DD; Wenger, NK | 1 |
| Kishi, T; Sunagawa, K | 1 |
| Baigorria, ST; Eynard, AR; Fiore, MC; García, NH; Juncos, LA; Juncos, LI; Martín, FL; Pasqualini, ME | 1 |
| Budhiraja, RD; Sharma, S; Tyagi, S | 1 |
| Lazareva, NV; Oshchepkova, EV | 1 |
| Medvedev, IN; Skoriatina, IA | 1 |
| Delgado-Montero, A; Zamorano, JL | 1 |
| Raison, J; Rudnichi, A; Safar, ME | 1 |
| Beevers, DG; Lim, HS; Lip, GY; Nadar, S | 1 |
| Hirooka, Y; Kishi, T; Mukai, Y; Shimokawa, H; Takeshita, A | 1 |
| Lindholm, LH; Samuelsson, O | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 3 |
| Liebson, PR | 1 |
| SoRelle, R | 1 |
| Devroey, D; Ginst, LV | 1 |
| Killestein, J | 1 |
| Drummond, GA | 1 |
| Hackam, DG | 1 |
| Hedner, T; Himmelman, A; Kjeldsen, SE | 1 |
| Beniashvili, M; Freiman, A; Gavish, D; Leibovitz, E; Shargorodsky, M; Zimlichman, R | 1 |
| Brown, WV; Moussa, M | 1 |
| Scheen, AJ | 1 |
| Kjeldsen, S; Midtbø, K; Svilaas, A; Syvertsen, JO; Westheim, A | 1 |
| Davalos, A; Fisher, M | 1 |
| Blanco-Colio, LM; Egido, J; Osende, JI; Ruiz-Ortega, M | 1 |
| Jukema, JW; van der Hoorn, JW | 1 |
| Kadioglu, M; Kalyoncu, NI; Kesim, M; Ulku, C; Yaris, E; Yaris, F | 1 |
| McKerracher, A | 1 |
| Düsing, R; Klose, G; Szucs, TD | 1 |
| Jaimes, EA; Raij, L; Zhou, MS | 1 |
| Madsen, S | 1 |
| Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A | 1 |
| Abdalla, DS; Aldrighi, JM; Bertolami, MC; Faludi, AA; Nakamura, Y; Pereira, IR; Ramires, JA; Saleh, MH; Silva, RA; Sousa, JE | 1 |
| Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR | 1 |
| Berezovsky, A; Laszt, A; London, D; Magen, E; Mishal, J; Priluk, R; Viskoper, R; Yosefy, C | 1 |
| Barraclough, D; Colman, PG; Reed, MD | 1 |
| Fushimi, H | 1 |
| Cárcamo, CA; Celedón, C; Nygren, CE; Paulós, CP | 1 |
| Blanco, S; Egido, J; Gómez-Guerrero, C; López, D; Romero, R; Vaquero, M | 1 |
| Ahishali, B; Arican, N; Bilgic, B; Elmas, I; Kalayci, R; Kaya, M; Kucuk, M; Kudat, H; Uzun, H | 1 |
| Blank, R; LaSalle, J; Maroni, J; Reeves, R; Sun, F; Tarasenko, L | 1 |
| Akcay, A; Bilgi, M; Bozbas, H; Kanbay, M; Muderrisoglu, H; Ozdemir, FN; Ulus, T; Yildirir, A | 1 |
| Cowie, MR | 1 |
| Gao, YJ; Lee, RM; Yang, L | 1 |
| Field, KM | 1 |
| Hobbs, FD | 1 |
| Bauer, B; Böhler, S; da Silva, PM; Feldman, R; Genest, J; Gensini, G; Harvey, P; Hobbs, FD; Jenssen, TG; Mancini, GB; Manolis, AJ; Metcalfe, M | 1 |
| Clearfield, M | 1 |
| Lynch, T | 1 |
| Huang, TG; Mondo, CK; Su, JZ; Yang, WS | 2 |
| Blank, R | 1 |
| Plummer, CJ | 1 |
| Bakris, GL; Ferrera, D; Flack, JM; Houston, MC; Lee, E; Messerli, FH; Neutel, JM; Petrella, RJ; Sun, W | 1 |
| Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A | 1 |
| Demova, H; Kluckova, H; Komers, R; Lecian, D; Lodererova, A; Teplan, V; Voska, L; Zdychova, J | 1 |
| Carod-Artal, FJ | 1 |
| Huang, TG; Mondo, CK; Yang, WS; Zhang, N | 1 |
| Shah, DI; Singh, M | 2 |
| Blanco-Colio, LM; Duran, MC; Egido, J; Martín-Ventura, JL; Tuñon, J; Vivanco, F | 1 |
| Agustín Herrero, J; Cámara Hijón, C; Costo Campoamor, A; Crespo Rincón, L; Fernández Pereira, L; Pereira Navarro, G; Sánchez Muñoz-Torrero, JF; Torres Pérez, F | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, JA | 1 |
| Zhou, MS | 1 |
| McClendon, KS; Riche, DM | 1 |
| Katayama, Y; Katsumata, T; Nishiyama, Y; Otori, T; Tanaka, N | 1 |
| Hu, SJ; Sun, J; Zhang, ZJ | 1 |
| Bayés, B; Blanco, S; Bonet, J; Lauzurica, R; Navarro-Muñoz, M; Romero, R | 1 |
| Arca, M | 1 |
| Nisanci, Y; Oflaz, H; Pamukcu, B; Tirnaksiz, E | 1 |
| Hu, ZJ; Liu, DL; Wang, MP; Wu, G; Wu, J; Xu, GY | 1 |
| Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, M; Sillesen, H; Szarek, M; Welch, KM; Zivin, JA | 1 |
| Bruschi, P; Ferdinand, KC; Flack, JM; Jamieson, MJ; Saunders, E; Shi, H; Tarasenko, L; Victor, R; Watson, K | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlof, B; Kjeldsen, SE; Kristinsson, A; McInnes, G; Mehlsen, J; Nieminen, MS; O'Brien, ET; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, J | 1 |
| Adamidou, A; Giannopoulos, S; Hatzitolios, AI; Kosmidou, MS; Milionis, HJ; Parharidis, G; Raikos, N | 1 |
| Cappelleri, JC; Dubois, RW; Messerli, FH; Pinto, L; Sichrovsky, T; Tang, SS; Thakker, KM | 1 |
| Jesmin, S; Kato, N; Liang, YQ; Ochiai, Y | 1 |
| McKeage, K; Siddiqui, MA | 1 |
| Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF | 1 |
| Pretnar-Oblak, J; Sabovic, M; Sebestjen, M | 1 |
| Breazna, A; Deedwania, PC; Kostis, JB; LaRosa, JC | 1 |
| Cachofeiro, V; Lahera, V | 1 |
| Cooper, A; Kratzer, S; Pershad, A | 1 |
| Ahlbory, K; Bäumer, AT; Böhm, M; Itter, G; Laufs, U; Linz, W; Müller, K; Nickenig, G; Rösen, R; Wassmann, S | 1 |
| Ichihara, K; Kaneta, S; Marumo, H; Satoh, K; Yamamoto, A | 1 |
| Ahlbory, K; Bäumer, AT; Böhm, M; Konkol, C; Laufs, U; Linz, W; Müller, K; Nickenig, G; Wassmann, S | 1 |
| Baguet, JP; Cameron, JD; Dart, AM; Ferrier, KE; Jennings, GL; Kingwell, BA; Muhlmann, MH | 1 |
| Banga, JD; Bots, ML; Huisman, MV; Stolk, RP; van de Ree, MA; van Venrooij, FV | 1 |
26 review(s) available for atorvastatin and Hypertension
| Article | Year |
|---|---|
Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Renin-Angiotensin System | 2022 |
A systematic review and meta-analyses on the effects of atorvastatin on blood pressure and heart rate.
Topics: Animals; Atorvastatin; Blood Pressure; Cholesterol; Heart Rate; Humans; Hypertension; Rats | 2022 |
[Lipertance® The ASCOT single-pill combination has finally arrived].
Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Humans; Hypertension; Perindopril; Risk Factors | 2017 |
A low-density lipoprotein-dependent effect of atorvastatin upon the systolic blood pressure reduction: meta-regression analyses of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Pressure; Heptanoic Acids; Humans; Hypertension; Lipoproteins, LDL; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Treatment Outcome | 2013 |
Expanding roles for atorvastatin.
Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Renal Insufficiency; Stroke | 2008 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Medication Adherence; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Quality of Life; Treatment Outcome | 2009 |
Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Pyrroles | 2010 |
Aldosterone, hypertension and heart failure: insights from clinical trials.
Topics: Aldosterone; Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Dihydrotestosterone; Drug Therapy, Combination; Enzyme Inhibitors; Female; Heart Failure; Heptanoic Acids; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Mice; Mineralocorticoid Receptor Antagonists; Ouabain; Pyrroles; Quinolines; Rats; Spironolactone | 2010 |
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Obesity; Office Visits; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Risk Assessment; Smoking; United States | 2010 |
Atorvastatin calcium plus amlodipine for the treatment of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Drug Combinations; Dyslipidemias; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2003 |
Emerging therapies for cerebrovascular disorders.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cerebrovascular Circulation; Cerebrovascular Disorders; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Intracranial Aneurysm; Pyrroles; Randomized Controlled Trials as Topic; Risk; Simvastatin; Therapeutics; Tissue Plasminogen Activator; Treatment Outcome | 2004 |
Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study.
Topics: Atorvastatin; Clinical Trials Data Monitoring Committees; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic | 2004 |
Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy.
Topics: Amlodipine; Animals; Arteriosclerosis; Atorvastatin; Calcium Channel Blockers; Combined Modality Therapy; Heptanoic Acids; Humans; Hypertension; Hypolipidemic Agents; Pyrroles | 2004 |
[Treatment of cerebral infarction patients with IGT].
Topics: Antidepressive Agents; Antipyrine; Atorvastatin; Cerebral Infarction; Edaravone; Free Radical Scavengers; Glucose Intolerance; Heptanoic Acids; Humans; Hyperglycemia; Hypertension; Hypertriglyceridemia; Insulin Resistance; Pyrroles; Secondary Prevention; Thrombolytic Therapy | 2005 |
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Pyrroles; Risk Factors; Treatment Outcome | 2005 |
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2005 |
Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Models, Biological; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Triglycerides | 2006 |
A single-pill combination of amlodipine besylate and atorvastatin calcium.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Clinical Trials as Topic; Drug Combinations; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Pyrroles; Tablets | 2006 |
What's in the CARDS?
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Smoking | 2006 |
Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients.
Topics: Amlodipine; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Calcium Channel Blockers; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2006 |
Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Randomized Controlled Trials as Topic | 2007 |
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Stroke | 2007 |
Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutics | 2008 |
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2008 |
84 trial(s) available for atorvastatin and Hypertension
| Article | Year |
|---|---|
Role of plasma extracellular vesicles in prediction of cardiovascular risk and alterations in response to statin therapy in hypertensive patients.
Topics: Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Endothelial Cells; Extracellular Vesicles; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Risk Factors | 2022 |
Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial.
Topics: Amlodipine; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Humans; Hypertension; Microcirculation; Receptors, Retinoic Acid; RNA; T-Lymphocytes, Regulatory; Th17 Cells | 2023 |
Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia.
Topics: Amlodipine; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Humans; Hypertension; Leukemia, Myeloid, Acute; Rosuvastatin Calcium; Treatment Outcome | 2023 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Health Centers; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Medically Underserved Area; Medication Adherence; Middle Aged | 2019 |
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension p
Topics: Adult; Aged; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Hematologic Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Lymphatic Diseases; Male; Middle Aged; Muscular Diseases; Nocebo Effect; Risk Factors; Sleep Wake Disorders; Treatment Outcome | 2017 |
Do Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Region with Mild-to-Moderate Iodine Deficiency? A Prospective Study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Life Style; Lipids; Male; Middle Aged; Prospective Studies; Rosuvastatin Calcium; Thyroid Function Tests; Thyroid Gland; Thyroid Nodule | 2018 |
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cause of Death; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Risk Factors; United Kingdom | 2018 |
A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Blood Glucose; Blood Pressure; China; Dyslipidemias; Equivalence Trials as Topic; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Multicenter Studies as Topic; Prediabetic State; Prospective Studies; Quinolines; Time Factors; Treatment Outcome; Young Adult | 2018 |
Comparison and analysis of statins drug use in the treatment of diastolic dysfunction in patients.
Topics: Aged; Atorvastatin; Blood Pressure; Double-Blind Method; Echocardiography; Exercise; Exercise Tolerance; Female; Heart Failure, Diastolic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Ventricular Function, Left | 2018 |
Post Hoc Analysis of the CONFIDENCE II, PROTECT I, SHAKE THE HABIT I and SHAKE THE HABIT II Observational Studies in Mild to Moderate Hypertensive Patients Treated with Perindopril and Atorvastatin Concomitantly.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Atorvastatin; Blood Pressure; Canada; Cohort Studies; Female; Humans; Hypertension; Male; Middle Aged; Perindopril; Prospective Studies; Treatment Outcome | 2018 |
Efficacy of a fixed dose combination of irbesartan and atorvastatin (Rovelito
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Prospective Studies; Surveys and Questionnaires | 2019 |
Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Aorta; Atorvastatin; Blood Pressure; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemodynamics; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pulse Wave Analysis; Pyrroles; Treatment Outcome; Vascular Stiffness | 2013 |
Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Coronary Disease; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Risk Factors | 2013 |
Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Treatment Outcome | 2013 |
Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2014 |
Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Risk Factors; Treatment Outcome; Triglycerides | 2013 |
Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Diuretics; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Prevalence; Pyrroles; Risk Factors; Treatment Outcome | 2014 |
[Effect of atorvastatin on exercise tolerance in patients with diastolic dysfunction and exercise-induced hypertension].
Topics: Aged; Atorvastatin; C-Reactive Protein; Double-Blind Method; Endothelins; Exercise Tolerance; Female; Heart Failure; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyrroles | 2014 |
[The influence of citoflavin on molecular mechanisms of hypertensive encephalopathy development in patients with systolic arterial hypertension].
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Atorvastatin; Blood Pressure; Blood Proteins; Drug Combinations; Drug Therapy, Combination; Echocardiography; Female; Flavin Mononucleotide; Hemodynamics; Heptanoic Acids; Humans; Hypertension; Hypertensive Encephalopathy; Inosine Diphosphate; Male; Neuroprotective Agents; Niacinamide; Pyrroles; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Succinates; Systole; Tetrazoles; Valine; Valsartan | 2014 |
Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Cause of Death; Cholesterol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Renal Dialysis; Risk Factors; Serum Albumin; Survival Rate; Troponin T; Uremia | 2015 |
[Pleiotropic effects of atorvastatin and dynamics of quality of life characteristics in patients with hypertensive disease and metabolic syndrome].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypertension; Metabolic Syndrome; Middle Aged; Pyrroles; Quality of Life; Treatment Outcome | 2013 |
Combined effect of appointment telmisartan and atorvastatin on hemodynamic indicators and the indicators of lipid profile in patients with arterial hypertension combined with obesity and steatohepatitis.
Topics: Acetamides; Adipokines; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Benzoates; Breath Tests; Cholesterol, LDL; Drug Therapy, Combination; Fatty Liver; Female; Hemodynamics; Heptanoic Acids; Humans; Hypertension; Lipids; Male; Middle Aged; Obesity; Pyrroles; Telmisartan; Triglycerides | 2014 |
Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Fasting; Female; Humans; Hypertension; Male; Metabolic Syndrome; Middle Aged; Predictive Value of Tests; Risk Factors; Triglycerides | 2016 |
Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering
Topics: Adult; Aged; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Clinical Decision-Making; Decision Support Techniques; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipids; Male; Middle Aged; Myocardial Infarction; North America; Predictive Value of Tests; Protective Factors; Reproducibility of Results; Risk Assessment; Risk Factors; Scandinavian and Nordic Countries; Time Factors; Treatment Outcome; United Kingdom | 2016 |
Effects of 12 weeks of atorvastatin therapy on myocardial fibrosis and circulating fibrosis biomarkers in statin-naïve patients with hypertension with atherosclerosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Electrocardiography; Female; Fibrosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Myocardium | 2016 |
Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factorial, Multicenter Phase III Study.
Topics: Aged; Antihypertensive Agents; Atorvastatin; Biphenyl Compounds; Blood Pressure; Cholesterol; Double-Blind Method; Drug Combinations; Female; Humans; Hypercholesterolemia; Hypertension; Irbesartan; Male; Middle Aged; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome | 2016 |
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
Topics: Apolipoprotein A-I; Atorvastatin; Blood Pressure; Cholesterol; Data Interpretation, Statistical; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Male; Middle Aged; Pyrroles; Reproducibility of Results; Sex Characteristics; Sex Factors; Stroke; Treatment Outcome; Triglycerides | 2008 |
Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyrroles; Treatment Outcome | 2009 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Pyrroles; Regional Blood Flow; Severity of Illness Index; Vasodilation | 2008 |
Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Carotid Artery Diseases; Carotid Stenosis; Chemokine CCL2; Cholesterol, LDL; Drug Synergism; Female; Heptanoic Acids; Humans; Hypertension; Macrophages; Male; Middle Aged; NF-kappa B; Pyrroles; RNA, Messenger | 2008 |
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia.
Topics: Adult; Aged; Amlodipine; Arteries; Atorvastatin; Compliance; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Placebos; Pyrroles | 2009 |
Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.
Topics: Aorta; Atorvastatin; Blood Pressure; Brachial Artery; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Placebos; Pulsatile Flow; Pyrroles; Radial Artery; Treatment Outcome | 2009 |
The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study.
Topics: Amlodipine; Analysis of Variance; Atorvastatin; Calcium Channel Blockers; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Life Style; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome | 2009 |
Coronary heart disease benefits from blood pressure and lipid-lowering.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Coronary Disease; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Risk Factors; Risk Reduction Behavior; Sodium Chloride Symporter Inhibitors | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Canada; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Europe; Female; Heptanoic Acids; Humans; Hypertension; Lipid Metabolism; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Tablets; Treatment Outcome | 2009 |
Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Baroreflex; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Pressoreceptors; Pyrroles | 2009 |
Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Cross-Over Studies; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Severity of Illness Index; Single-Blind Method | 2011 |
Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT).
Topics: Aged; Amlodipine; Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure Determination; Carotid Arteries; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Probability; Prospective Studies; Pulsatile Flow; Pyrroles; Reproducibility of Results; Scandinavian and Nordic Countries; Severity of Illness Index; United Kingdom; Vasodilator Agents | 2009 |
Influence of atorvastatin on blood pressure control in treated hypertensive, normolipemic patients - An open, pilot study.
Topics: Adult; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cholesterol; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypertension; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Pilot Projects; Pyrroles; Triglycerides | 2010 |
Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cluster Analysis; Drug Combinations; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Internationality; Male; Middle Aged; Primary Prevention; Prospective Studies; Pyrroles; Research Design; Risk Assessment; Risk Factors; Surveys and Questionnaires | 2010 |
[Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension].
Topics: Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Psoriasis; Pyrroles; Quality of Life; Severity of Illness Index; Skin; Treatment Outcome | 2010 |
Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
Topics: Aged, 80 and over; Amlodipine; Angina, Stable; Antihypertensive Agents; Atorvastatin; Chronic Disease; Double-Blind Method; Drug Combinations; Electrocardiography, Ambulatory; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Young Adult | 2010 |
The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Cost-Benefit Analysis; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Markov Chains; Medication Adherence; Middle Aged; Pyrroles; Quality-Adjusted Life Years; Risk Factors | 2010 |
J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial.
Topics: Adult; Aged; Antihypertensive Agents; Atorvastatin; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Arrest; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2010 |
Sympathoinhibition by atorvastatin in hypertensive patients.
Topics: Adolescent; Adult; Aged; Animals; Atorvastatin; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Norepinephrine; Prospective Studies; Pyrroles; Sympathetic Nervous System; Time Factors | 2010 |
What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TI
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prognosis; Proportional Hazards Models; Pyrroles; Risk Factors; Thrombolytic Therapy; Treatment Outcome | 2010 |
Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm.
Topics: Adult; Age Factors; Aged; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipids; Male; Middle Aged; Pyrroles | 2011 |
Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Preventive Health Services; Pyrroles; Risk Factors; Standard of Care | 2011 |
High-dose atorvastatin enhances impaired cerebral vasomotor reactivity.
Topics: Aged; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Flow Velocity; Blood Pressure; Brain Infarction; Cerebrovascular Circulation; Chi-Square Distribution; Cholesterol, LDL; Female; Florida; Hemodynamics; Heptanoic Acids; Hispanic or Latino; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Middle Cerebral Artery; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Transcranial | 2012 |
Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Topics: Aged; Atorvastatin; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Ireland; Male; Middle Aged; Pyrroles; Racial Groups; Treatment Outcome; United Kingdom | 2011 |
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Stroke; Treatment Outcome | 2012 |
Improving adherence with amlodipine/atorvastatin therapy: IMPACT study.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or African American; Blood Pressure; Cholesterol; Comorbidity; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypertension; Lipoproteins, LDL; Male; Middle Aged; Patient Compliance; Pyrroles; Treatment Outcome | 2011 |
The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.
Topics: Adult; Aged; Atorvastatin; Cause of Death; Coronary Disease; Double-Blind Method; Early Termination of Clinical Trials; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2011 |
Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomized, placebo-controlled study.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2012 |
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cardiopulmonary Resuscitation; Cholesterol, LDL; Death, Sudden, Cardiac; Female; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk; Sex Factors; Stroke | 2012 |
Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study.
Topics: Adult; Aged; Anticholesteremic Agents; Aorta; Atorvastatin; Blood Pressure; Double-Blind Method; Elasticity; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pulse; Pyrroles; Statistics, Nonparametric; Treatment Outcome | 2002 |
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Risk Factors; Stroke | 2003 |
LIFE and ARBITER.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pravastatin; Pyrroles; Treatment Outcome | 2003 |
[Statin therapy for hypertensive patients].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles | 2004 |
Treating to hypertension targets.
Topics: Adrenergic beta-Antagonists; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Determination; Coronary Disease; Female; Heptanoic Acids; Humans; Hypertension; Male; Pyrroles | 2004 |
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Drug Therapy, Combination; Female; Fibrinolysis; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Insulin Resistance; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Tissue Plasminogen Activator | 2004 |
Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects.
Topics: Aged; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Estrogens; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Middle Aged; Norethindrone; Progesterone; Pyrroles; Vasodilation | 2004 |
Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Ascorbic Acid; Atorvastatin; Blood Pressure; Brachial Artery; Cross-Sectional Studies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrroles | 2004 |
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Topics: Atorvastatin; Coronary Artery Disease; Cost-Benefit Analysis; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Placebos; Pyrroles; Stroke; Treatment Outcome | 2005 |
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
Topics: Adult; Aged; Atorvastatin; Cholesterol; Coronary Disease; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Scandinavian and Nordic Countries; Stroke; Treatment Outcome; United Kingdom | 2004 |
Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia.
Topics: Aged; Atorvastatin; Chile; Community Pharmacy Services; Drug-Related Side Effects and Adverse Reactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Patient Compliance; Patient Education as Topic; Patient Satisfaction; Pyrroles; Quality of Life | 2005 |
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke | 2005 |
Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study).
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atorvastatin; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2005 |
Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients.
Topics: Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Outpatients; Pyrroles; Treatment Outcome; Triglycerides | 2005 |
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
Topics: Adolescent; Adult; Aged; Amlodipine; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2006 |
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Biomarkers; Blood Glucose; Body Mass Index; Calcium Channel Blockers; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation; Insulin Resistance; Interleukin-6; Male; Middle Aged; Obesity; Pyrroles; Tablets; Tumor Necrosis Factor-alpha | 2006 |
Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation?
Topics: Adult; Aged; Atorvastatin; Blood Pressure; Cohort Studies; Dyslipidemias; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Proteinuria; Pyrroles; Transforming Growth Factor beta | 2007 |
Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Collagen; Coronary Disease; Diabetes Complications; Drug Resistance; Epinephrine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Pyrroles; Smoking | 2009 |
[Effect of atorvastatin on carotid intima-medial of thickness of primary hypertension patients of Han nationality in China].
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzazepines; Carotid Arteries; China; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media | 2007 |
A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial.
Topics: Alanine Transaminase; Alkaline Phosphatase; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Aspartate Aminotransferases; Atorvastatin; Blood Pressure; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Hypertension; Male; Pyrroles; Treatment Outcome | 2007 |
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol, LDL; Comorbidity; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Pyrroles; Risk Assessment; Secondary Prevention; Sex Factors | 2008 |
Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or African American; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2008 |
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Epidemiologic Methods; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke | 2008 |
Effects of atorvastatin on red-blood cell Na(+)/Li(+) countertransport in hyperlipidemic patients with and without hypertension.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Biological Transport; Blood Pressure; Cholesterol; Dose-Response Relationship, Drug; Erythrocytes; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Insulin Resistance; Linear Models; Lithium; Male; Middle Aged; Pyrroles; Sodium; Triglycerides | 2008 |
Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Uric Acid; Ventricular Remodeling | 2008 |
The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Systole; Time Factors; Treatment Outcome | 2008 |
Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension.
Topics: Aged; Alanine Transaminase; Arteries; Aspartate Aminotransferases; Atorvastatin; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Hemodynamics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Patient Compliance; Pyrroles; Systole; Triglycerides; Victoria | 2002 |
Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Lipids; Male; Middle Aged; Placebos; Pyrroles; Smoking; Vasodilation | 2002 |
149 other study(ies) available for atorvastatin and Hypertension
| Article | Year |
|---|---|
Spectral-Domain OCT Imaging of Lipemia Retinalis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Diabetes Complications; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Middle Aged; Retinal Diseases; Tomography, Optical Coherence; Triglycerides | 2021 |
Dose-dependent atorvastatin associated with angioedema.
Topics: Aged; Amlodipine; Angioedema; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Female; Humans; Hypertension; Losartan | 2022 |
Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart Study: A 8-year follow-up.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Perindopril | 2022 |
Related Factors of Cerebral Hemorrhage after Cerebral Infarction and the Effect of Atorvastatin Combined with Intensive Nursing Care.
Topics: Adult; Atorvastatin; Atrial Fibrillation; Case-Control Studies; Cerebral Hemorrhage; Cerebral Infarction; Humans; Hypertension; Retrospective Studies; Stroke; Tablets | 2022 |
Combining LC-MS/MS profiles with network pharmacology to predict molecular mechanisms of the hyperlipidemic activity of Lagenaria siceraria stand.
Topics: Animals; Atorvastatin; Chromatography, Liquid; Cucurbita; Flavonoids; Glycosides; Hesperidin; Hyperlipidemias; Hypertension; Insulins; Network Pharmacology; Obesity; Plant Extracts; Proto-Oncogene Proteins c-akt; Rats; Tandem Mass Spectrometry | 2023 |
Effects of Long-Term Intervention with Losartan, Aspirin and Atorvastatin on Vascular Remodeling in Juvenile Spontaneously Hypertensive Rats.
Topics: Animals; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Collagen; Hypertension; Interleukin-6; Losartan; Rats; Rats, Inbred SHR; Renin; Vascular Remodeling | 2023 |
The L-shaped correlation between systolic blood pressure and short-term and long-term mortality in patients with cerebral hemorrhage.
Topics: Atorvastatin; Blood Pressure; Cefdinir; Cerebral Hemorrhage; Cerebral Infarction; Humans; Hypertension; Hypotension | 2023 |
Atorvastatin rescues vascular endothelial injury in hypertension by WWP2-mediated ubiquitination and degradation of ATP5A.
Topics: Animals; Atorvastatin; Endothelial Cells; Hypertension; Mice; Mice, Knockout; Ubiquitin-Protein Ligases; Ubiquitination | 2023 |
Application of Atorvastatin Combined with Ezetimibe in Elderly Patients with Hypertension Combined with T2DM and Analysis of Significance of Changes in Serum Bilirubin Levels During Treatment.
Topics: Aged; Atorvastatin; Bilirubin; Diabetes Mellitus, Type 2; Ezetimibe; Glucose; Humans; Hypertension | 2023 |
[Can a lipophilic statin improve the treatment of heart failure with preserved ejection fraction in patients with hypertension and obesity?]
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Obesity; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2023 |
Response Letter to Letter by Venu Jonnalagadda.
Topics: Atorvastatin; China; Dyslipidemias; Glucose; Glycated Hemoglobin; Humans; Hypertension; Prediabetic State; Quinolines | 2019 |
Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Databases, Factual; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Italy; Lipids; Male; Medication Adherence; Middle Aged; Perindopril; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Importance of fixed-dose combinations in cardiovascular prevention: the possibility of treating two diagnoses with a single pill.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Humans; Hypertension; Perindopril | 2020 |
Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Humans; Hypertension; Mortality; Taiwan; Treatment Outcome | 2020 |
Euvascor - early intervention of hypertension and dyslipidaemia (dual combination of atorvastatin and perindopril).
Topics: Atorvastatin; Cardiovascular Diseases; Czech Republic; Dyslipidemias; Humans; Hypertension; Perindopril | 2020 |
[Fixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of cardiovascular risk management].
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Heart Disease Risk Factors; Humans; Hypertension; Perindopril; Risk Factors | 2021 |
Combination of atorvastatin or hydrochlorothiazide/amlodipine with
Topics: Amlodipine; Atherosclerosis; Atorvastatin; Drugs, Chinese Herbal; Humans; Hydrochlorothiazide; Hyperlipidemias; Hypertension; Pueraria; Salvia miltiorrhiza | 2021 |
Long-Term Incidence of Stroke and Dementia in ASCOT.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Dementia; Female; Humans; Hypertension; Incidence; Male; Middle Aged; Risk Factors; Scandinavian and Nordic Countries; Stroke; Treatment Outcome; United Kingdom | 2021 |
Statin Treatment and Clinical Outcomes of Heart Failure Among Africans: An Inverse Probability Treatment Weighted Analysis.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Black People; Cardiomyopathy, Dilated; Cardiovascular Diseases; Cause of Death; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Fatty Acids, Monounsaturated; Fluvastatin; Ghana; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Kaplan-Meier Estimate; Longitudinal Studies; Middle Aged; Mortality; Multivariate Analysis; Probability; Proportional Hazards Models; Renal Insufficiency, Chronic; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2017 |
Effect of Atorvastatin on lower extremity function of patients with hypertension and peripheral arterial disease.
Topics: Atorvastatin; Blood Pressure; Female; Humans; Hypertension; Lower Extremity; Male; Peripheral Arterial Disease; Walking | 2017 |
Does a fixed-dose combination of amlodipine and atorvastatin improve persistence with therapy in the Australian population?
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Australia; Cohort Studies; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Medication Adherence; Middle Aged; Patient Dropouts; Proportional Hazards Models; Risk Assessment | 2018 |
Can aldosterone break your heart? Takotsubo cardiomyopathy in a patient with newly diagnosed primary aldosteronism.
Topics: Aldosterone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Chest Pain; Coronary Angiography; Electrocardiography; Female; Humans; Hyperaldosteronism; Hypertension; Metoprolol; Middle Aged; Takotsubo Cardiomyopathy; Treatment Outcome | 2018 |
Atorvastatin might resist tobacco smoking-induced endothelial inflammation through the inhibition of NF-κB signal pathway.
Topics: Atorvastatin; Cells, Cultured; Complex Mixtures; E-Selectin; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation; NF-kappa B; Signal Transduction; Tobacco Smoking; Vascular Cell Adhesion Molecule-1 | 2019 |
Atorvastatin Attenuates Myocardial Hypertrophy in Spontaneously Hypertensive Rats via the C/EBPβ/PGC-1α/UCP3 Pathway.
Topics: Animals; Apoptosis; Atorvastatin; Atrial Natriuretic Factor; Blood Pressure; CCAAT-Enhancer-Binding Protein-beta; Echocardiography; Hypertension; Hypertrophy; Male; Myocardium; Myocytes, Cardiac; Natriuretic Peptide, Brain; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Uncoupling Protein 3; Up-Regulation; Ventricular Remodeling | 2018 |
Atorvastatin, losartan and captopril may upregulate IL-22 in hypertension and coronary artery disease; the role of gene polymorphism.
Topics: Adult; Aged; Atorvastatin; Captopril; Case-Control Studies; Coronary Artery Disease; Female; Genotype; Humans; Hypertension; Interleukin-22; Interleukins; Iran; Losartan; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Up-Regulation | 2018 |
A Thorny Finding: Unexpected Acanthocytosis in an Elderly Patient.
Topics: Abetalipoproteinemia; Aged; Atherosclerosis; Atorvastatin; Diabetes Complications; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Parkinson Disease | 2018 |
Prediabetes with Hypertension and Dyslipidemia: Are They Triad of Future Cardiovascular Risk?
Topics: Atorvastatin; Cardiovascular Diseases; China; Dyslipidemias; Glucose; Glycated Hemoglobin; Humans; Hypertension; Prediabetic State; Quinolines; Risk Factors | 2019 |
Atorvastatin alleviates early hypertensive renal damage in spontaneously hypertensive rats.
Topics: Animals; Atorvastatin; Blood Pressure; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation Mediators; Kidney Diseases; Male; Rats; Rats, Inbred SHR | 2019 |
Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: The role of gene polymorphism.
Topics: Atorvastatin; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Genotype; Humans; Hypertension; Losartan; Male; Middle Aged; Monoamine Oxidase; Polymorphism, Single Nucleotide | 2019 |
Clinical features related to statin-associated muscle symptoms.
Topics: Aged; Atorvastatin; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Lovastatin; Male; Medical History Taking; Middle Aged; Muscle Weakness; Muscular Diseases; Myalgia; Obesity; Odds Ratio; Pravastatin; Retrospective Studies; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; White People | 2019 |
Atorvastatin Prevents Myocardial Fibrosis in Spontaneous Hypertension via Interleukin-6 (IL-6)/Signal Transducer and Activator of Transcription 3 (STAT3)/Endothelin-1 (ET-1) Pathway.
Topics: Animals; Atorvastatin; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Endomyocardial Fibrosis; Endothelin-1; Fibrosis; Hypertension; Interleukin-6; Male; Myocardium; Phosphorylation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; STAT3 Transcription Factor | 2019 |
Simultaneous transient global amnesia and Takotsubo syndrome after death of a relative: a case report.
Topics: Amnesia, Transient Global; Antihypertensive Agents; Aspirin; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Bisoprolol; Coronary Angiography; Electrocardiography; Fibrinolytic Agents; Grief; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocarditis; Stress, Psychological; Takotsubo Cardiomyopathy; Tetrazoles; Treatment Outcome | 2019 |
Schimke immunoosseous dysplasia and management considerations for vascular risks.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Atorvastatin; Benzazepines; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Child; Disease Management; DNA Helicases; Dyslipidemias; Female; Gene Expression; Headache; Humans; Hypertension; Mutation; Nephrotic Syndrome; Osteochondrodysplasias; Primary Immunodeficiency Diseases; Propranolol; Pulmonary Embolism | 2019 |
Treatment of Hypertensive and Hypercholesterolaemic Patients with the Triple Fixed Combination of Atorvastatin, Perindopril and Amlodipine: The Results of the CORAL Study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Comorbidity; Drug Combinations; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Perindopril; Prospective Studies | 2019 |
Atorvastatin Attenuates Cold-Induced Hypertension by Preventing Gut Barrier Injury.
Topics: Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Aorta, Thoracic; Arterial Pressure; Atorvastatin; Cold Temperature; Colon; Cytokines; Disease Models, Animal; Hypertension; Hypothermia, Induced; Inflammation Mediators; Intestinal Mucosa; Nitric Oxide; Nitric Oxide Synthase Type III; Permeability; Phosphorylation; Rats, Sprague-Dawley; Signal Transduction; Tight Junctions | 2019 |
Factors associated with statin selection among privately insured commercial and Medicare patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult | 2013 |
Effects of atorvastatin on the hypertension-induced oxidative stress in the rat brain.
Topics: Animals; Atorvastatin; Blood Pressure; Brain; Cardiomegaly; Catalase; Glutathione; Heptanoic Acids; Hypertension; Male; Malondialdehyde; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Superoxide Dismutase | 2013 |
Acute vascular effects of atorvastatin in hypertensive men: a pilot study.
Topics: Angiotensin II; Atorvastatin; Endothelium, Vascular; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pilot Projects; Pyrroles; Regional Blood Flow; Vasoconstriction; Vasodilation | 2013 |
The effects of atorvastatin on oxidative stress in L-NAME-treated rats.
Topics: Animals; Aryldialkylphosphatase; Atorvastatin; Drug Evaluation, Preclinical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipid Peroxidation; Lipids; Male; NG-Nitroarginine Methyl Ester; Oxidative Stress; Protein Carbonylation; Pyrroles; Rats; Rats, Wistar; Sulfhydryl Compounds | 2013 |
Effect of atorvastatin on left atrial function of patients with paroxysmal atrial fibrillation.
Topics: Adult; Atorvastatin; Atrial Fibrillation; Atrial Function, Left; Echocardiography; Female; Heart Atria; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles | 2013 |
Statins decrease mean platelet volume irrespective of cholesterol lowering effect.
Topics: Adult; Atorvastatin; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Mean Platelet Volume; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2013 |
Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Atorvastatin; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy; Male; Nitric Oxide Synthase Type III; Pyrroles; Rats, Inbred Dahl; Scavenger Receptors, Class E; Sodium Chloride, Dietary; Superoxides; Time Factors; Vasodilation | 2014 |
Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release.
Topics: Administration, Oral; Atenolol; Atorvastatin; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Combinations; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Solubility | 2014 |
Atorvastatin combining with probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure.
Topics: Acute Kidney Injury; Aged; Antioxidants; Atorvastatin; Biomarkers; Contrast Media; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Function Tests; Male; Middle Aged; Perioperative Period; Probucol; Prospective Studies; Pyrroles; Risk Factors; Uric Acid | 2014 |
Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats.
Topics: Animals; Atorvastatin; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Heart Failure, Diastolic; Heptanoic Acids; HSP47 Heat-Shock Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Myocardium; Pyrroles; Rats; Rats, Inbred Dahl; rho-Associated Kinases; Ventricular Function, Left | 2014 |
Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Capsules; Drug Therapy, Combination; Female; Glucose; Heptanoic Acids; Humans; Hypertension; Inflammation; Kidney; Kidney Function Tests; Lipid Metabolism; Male; Multivariate Analysis; Oxidative Stress; Pyrroles; Regression Analysis; Renal Insufficiency, Chronic | 2014 |
A calcified left ventricular mass.
Topics: Aged, 80 and over; Aging; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Calcinosis; Diagnosis, Differential; Female; Heart Neoplasms; Heart Valve Diseases; Heptanoic Acids; Humans; Hypertension; Mitral Valve; Monitoring, Physiologic; Platelet Aggregation Inhibitors; Pyrroles; Quinapril; Radiography; Tetrahydroisoquinolines; Treatment Outcome | 2014 |
If I had resistant hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Pyrroles; Spironolactone; Tetrazoles; Treatment Failure; Treatment Outcome | 2014 |
Atorvastatin ameliorates arsenic-induced hypertension and enhancement of vascular redox signaling in rats.
Topics: Animals; Aorta, Thoracic; Arsenites; Atorvastatin; Catalase; Cholesterol; Glutathione Peroxidase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; NADPH Oxidase 4; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Pyrroles; Random Allocation; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Sodium Compounds; Superoxide Dismutase; Tyrosine | 2014 |
Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.
Topics: Aged; Atorvastatin; C-Reactive Protein; Comorbidity; Coronary Artery Disease; Diabetic Angiopathies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sex Factors; Sulfonamides; Ultrasonography, Interventional | 2014 |
[Effect of atorvastatin on pro-inflammatory status (in vivo and in vitro) in patients with essential hypertension and metabolic syndrome].
Topics: Anticholesteremic Agents; Atorvastatin; Cytokines; Dose-Response Relationship, Drug; Drug Monitoring; Essential Hypertension; Female; Heptanoic Acids; Humans; Hypertension; Inflammation; Leukocytes, Mononuclear; Male; Metabolic Syndrome; Middle Aged; Patient Acuity; Prospective Studies; Pyrroles; Reactive Oxygen Species; Severity of Illness Index; Treatment Outcome | 2014 |
Atorvastatin enhanced nitric oxide release and reduced blood pressure, nitroxidative stress and rantes levels in hypertensive rats with diabetes.
Topics: Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Glucose; Blood Pressure; Chemokine CCL5; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endothelial Cells; Hypertension; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Peroxynitrous Acid; Rats, Inbred SHR | 2015 |
High Incidence of ACE/PAI-1 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of ACE Inhibitor and Statin.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cytokines; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lebanon; Male; Middle Aged; Peptidyl-Dipeptidase A; Plasminogen Activator Inhibitor 1; Polymorphism, Single Nucleotide; Ramipril; Treatment Outcome; Young Adult | 2015 |
Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study.
Topics: Aged; Atorvastatin; Case-Control Studies; Comorbidity; Diabetes Mellitus; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Indoles; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pneumonia; Protective Factors; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Taiwan | 2016 |
Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats.
Topics: Administration, Oral; Amlodipine; Animals; Antihypertensive Agents; Atorvastatin; Cardiomegaly; Cross-Sectional Studies; Disease Models, Animal; Gene Expression Profiling; Hydroxyproline; Hypertension; Immunohistochemistry; Male; Myocardium; NF-kappa B; Osteoprotegerin; RANK Ligand; Rats, Inbred SHR; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Ventricular Function, Left | 2016 |
[One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Linear Models; Male; Medication Adherence; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2016 |
Effect of Low Dose Atorvastatin Therapy on Baroreflex Sensitivity in Hypertensives.
Topics: Aged; Antihypertensive Agents; Arterial Pressure; Atorvastatin; Autonomic Nervous System; Baroreflex; Cardiovascular System; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Time Factors; Treatment Outcome | 2016 |
Amlodipine and Atorvastatin Improved Hypertensive Cardiac Remodeling through Regulation of MMPs/TIMPs in SHR Rats.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blotting, Western; Drug Combinations; Gene Expression; Hypertension; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Random Allocation; Rats, Inbred SHR; Rats, Inbred WKY; Reverse Transcriptase Polymerase Chain Reaction; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinases; Ventricular Remodeling | 2016 |
Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Case-Control Studies; Disease Management; Drug Administration Schedule; Drug Combinations; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Patient Compliance; Pyrroles | 2016 |
Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Dyslipidemias; Female; Humans; Hypertension; Male; Middle Aged; Mortality; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin; Stroke | 2017 |
Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension.
Topics: Antihypertensive Agents; Atorvastatin; Captopril; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation; Interleukin-6; Interleukin-8; Iran; Losartan; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Up-Regulation | 2016 |
[Hypertension--does it matter how blood pressure is lowered?].
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Bendroflumethiazide; Cardiovascular Diseases; Cost-Benefit Analysis; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Treatment Outcome | 2008 |
Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen.
Topics: Aged; Amlodipine; Atorvastatin; Calcium Channel Blockers; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Patient Compliance; Pyrroles; Retrospective Studies | 2008 |
Effects of atorvastatin on calcium-regulating proteins: a possible mechanism to repair cardiac dysfunction in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blotting, Western; Calcium-Binding Proteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cytokines; Enzyme-Linked Immunosorbent Assay; Gene Expression; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pyrroles; Rats; Rats, Inbred SHR; Rats, Wistar; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Ventricular Function, Left | 2009 |
Effects of atorvastatin on warfarin-induced aortic medial calcification and systolic blood pressure in rats.
Topics: Animals; Aortic Diseases; Atorvastatin; Blood Pressure; Calcinosis; Heptanoic Acids; Hypertension; Male; Pyrroles; Random Allocation; Rats; Rats, Wistar; Warfarin | 2008 |
[Vascular prevention after cerebral infarct or transient ischemic accident. Recommendations. March, 2008].
Topics: Anticholesteremic Agents; Atorvastatin; Brain; Cerebral Infarction; Cerebrovascular Circulation; Coronary Disease; Heptanoic Acids; Humans; Hypertension; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Pyrroles; Risk Factors; Time Factors | 2008 |
Coronary plaque stabilization followed by Color Code Plaque analysis with 64-slice multidetector row computed tomography.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Stenosis; Coronary Vasospasm; Diabetes Complications; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Middle Aged; Pyrroles; Tomography, X-Ray Computed; Ultrasonography | 2009 |
[Brain hypoperfusion revealed by an ocular ischemic syndrome].
Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Brain Ischemia; Carotid Artery Thrombosis; Ciliary Body; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Ischemia; Light Coagulation; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Middle Aged; Ophthalmic Artery; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Stroke; Ultrasonography | 2008 |
Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure.
Topics: Atorvastatin; Biomarkers; Case-Control Studies; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Inflammation; Interferon-gamma; Interleukin-10; Interleukin-12; Interleukin-18; Interleukin-4; Male; Middle Aged; Pyrroles; Th1 Cells; Th2 Cells | 2009 |
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Chronic Disease; Coronary Disease; Epidemiologic Methods; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Time Factors; Treatment Outcome | 2009 |
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Models, Economic; Pyrroles; Scandinavian and Nordic Countries; Treatment Outcome | 2009 |
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
Topics: Age Factors; Aged; Atorvastatin; Causality; Cerebral Hemorrhage; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Iatrogenic Disease; Intracranial Arteriosclerosis; Male; Pyrroles; Sex Factors | 2009 |
Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection.
Topics: Animals; Aorta; Atorvastatin; Endothelium, Vascular; Gene Expression Regulation; Heptanoic Acids; Hypertension; Male; NG-Nitroarginine Methyl Ester; Pyrroles; Rats; Rats, Inbred F344 | 2009 |
Atorvastatin reverses cardiac remodeling possibly through regulation of protein kinase D/myocyte enhancer factor 2D activation in spontaneously hypertensive rats.
Topics: Animals; Atorvastatin; Blood Pressure; Disease Models, Animal; Enzyme Activation; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyproline; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; MEF2 Transcription Factors; Myocardium; Protein Kinase C; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Time Factors; Transcription Factors; Ventricular Remodeling | 2010 |
The functional changes of the perivascular adipose tissue in spontaneously hypertensive rats and the effects of atorvastatin therapy.
Topics: Adipose Tissue; Animals; Aorta, Thoracic; Atorvastatin; Connective Tissue; Disease Models, Animal; Endothelium-Dependent Relaxing Factors; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Vasoconstriction; Vasodilation | 2009 |
Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Black or African American; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2009 |
[Atorvastatin dreduces sympathetic activity and improves baroreceptor reflex sensitivity in patients with hypercholesterolemia and hypertension].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Baroreflex; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Pressoreceptors; Pyrroles | 2009 |
NADPH oxidase isoforms and anti-hypertensive effects of atorvastatin demonstrated in two animal models.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta, Thoracic; Apolipoproteins E; Atorvastatin; Blood Pressure; Blotting, Western; Dietary Fats; Ethidium; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Isoenzymes; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Nitric Oxide Synthase; Pyrroles; rac1 GTP-Binding Protein; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Atorvastatin improves the impaired baroreflex sensitivity via anti-oxidant effect in the rostral ventrolateral medulla of SHRSP.
Topics: Animals; Atorvastatin; Baroreflex; Blood Pressure; Disease Models, Animal; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Medulla Oblongata; Oxidative Stress; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2009 |
Sympathoinhibition induced by centrally administered atorvastatin is associated with alteration of NAD(P)H and Mn superoxide dismutase activity in rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
Topics: Animals; Atorvastatin; Baroreflex; Heptanoic Acids; Hypertension; Injections, Intraventricular; Male; Medulla Oblongata; NADP; Oxidative Stress; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Superoxide Dismutase; Sympathetic Nervous System | 2010 |
Clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; Diabetes Mellitus; Fatty Liver; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2010 |
Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Calcium Channel Blockers; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Managed Care Programs; Medication Adherence; Middle Aged; Odds Ratio; Pyrroles; Retrospective Studies | 2010 |
Approach to the patient who is intolerant of statin therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Coronary Disease; Diltiazem; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Middle Aged; Pyrroles; Simvastatin | 2010 |
The utility of observational studies in clinical decision making: lessons learned from statin trials.
Topics: Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Decision Making; Epidemiologic Studies; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Observation; Pyrroles; Simvastatin | 2010 |
Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Databases, Factual; Drug Therapy, Combination; Female; Health Records, Personal; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Risk; Risk Factors; Risk Reduction Behavior | 2010 |
[How to increase the adherence to treatment of patients with arterial hypertension and dyslipidemia: focus on fixed combination of amlodipine and atorvastatin].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Diuretics; Drug Combinations; Drug Monitoring; Drug Synergism; Dyslipidemias; Heart Diseases; Heptanoic Acids; Humans; Hypertension; Patient Compliance; Pyrroles; Risk Factors | 2010 |
[Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia].
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Viscosity; Data Interpretation, Statistical; Dyslipidemias; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Hematocrit; Hemorheology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Time Factors | 2010 |
Sympathoinhibitory effects of atorvastatin in hypertension.
Topics: Adolescent; Adult; Aged; Animals; Atorvastatin; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Norepinephrine; Prospective Studies; Pyrroles; Sympathetic Nervous System; Time Factors | 2010 |
[Effects of atorvastatin on p27 protein expression and cardiomyocytes apoptosis in spontaneously hypertensive rats].
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Cyclin-Dependent Kinase Inhibitor p27; Heptanoic Acids; Hypertension; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; RNA, Messenger | 2008 |
Hip circumference is associated with high density lipoprotein cholesterol response following statin therapy in hypertensive subjects.
Topics: Aged; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Waist Circumference; Waist-Hip Ratio | 2011 |
Long-term results from statin trials: answers but more unresolved questions.
Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pyrroles | 2011 |
Trastuzumab-related palmar plantar erythrodysaesthesia.
Topics: Aged; Amlodipine; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Antihypertensive Agents; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Foot Dermatoses; Hand Dermatoses; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Trastuzumab | 2012 |
Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Genome-Wide Association Study; Genotype; Glucosyltransferases; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Placebo Effect; Polymorphism, Single Nucleotide; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Lysophosphatidic Acid; Treatment Outcome | 2012 |
Improvement of arterial stiffness by reducing oxidative stress damage in elderly hypertensive patients after 6 months of atorvastatin therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Anticholesteremic Agents; Arteries; Atorvastatin; Biomarkers; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Statistics as Topic; Statistics, Nonparametric | 2012 |
Combination therapy of atorvastatin and amlodipine inhibits sympathetic nervous system activation and improves cognitive function in hypertensive rats.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Antioxidants; Atorvastatin; Cognition; Drug Therapy, Combination; Heptanoic Acids; Hippocampus; Hypertension; Male; Nerve Tissue Proteins; Pyrroles; Rats; Rats, Inbred SHR; Superoxide Dismutase; Sympathetic Nervous System | 2012 |
Atorvastatin improves sodium handling and decreases blood pressure in salt-loaded rats with chronic renal insufficiency.
Topics: Animals; Atorvastatin; Blood Pressure; Creatinine; Diet; Fatty Acids, Unsaturated; Heart Ventricles; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney; Male; Nephrectomy; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Proteinuria; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Sodium; Sodium Chloride, Dietary | 2012 |
Effect of phosphatidylinositol 3-kinase-γ inhibitor CAY10505 in hypertension, and its associated vascular endothelium dysfunction in rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Atorvastatin; Blood Pressure; Desoxycorticosterone; Endothelium, Vascular; Female; Glutathione; Heptanoic Acids; Hypertension; Losartan; Male; Nitrates; Nitrites; Phosphoinositide-3 Kinase Inhibitors; Pyrroles; Rats; Rats, Wistar; Thiazolidinediones | 2012 |
[Painless myocardial ischemia in patient with extensive constrictive atherosclerosis of coronary arteries].
Topics: Angioplasty; Anticholesteremic Agents; Asymptomatic Diseases; Atorvastatin; Cardiovascular Agents; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Echocardiography; Electrophysiologic Techniques, Cardiac; Exercise Test; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Severity of Illness Index; Treatment Outcome | 2012 |
[Dynamics of microrheologic properties of erythrocytes in patients with arterial hypertension and dyslipidemia treated with atorvastatin].
Topics: Anticholesteremic Agents; Atorvastatin; Comorbidity; Dyslipidemias; Erythrocytes; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles; Rheology; Severity of Illness Index | 2012 |
Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholesterol; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta; Atorvastatin; Blood Pressure; Brain; Genetic Predisposition to Disease; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Isoenzymes; Lipids; Male; Myocardium; Neural Inhibition; Nitric Oxide Synthase; Norepinephrine; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Sympathetic Nervous System; Up-Regulation | 2003 |
What are the odds at ASCOT today?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic | 2003 |
New lipid-lowering combo proves successful.
Topics: Atorvastatin; Attitude to Health; Azetidines; Drug Synergism; Drug Therapy, Combination; Europe; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Stroke; Treatment Outcome | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Complications; Female; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles; Sex Factors | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Heptanoic Acids; Humans; Hypertension; Pyrroles; Research Design | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black People; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Risk Factors | 2003 |
Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy?
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2003 |
Statins benefit people with high blood pressure.
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2003 |
In light of ALLHAT and ASCOT: are there benefits of statins as add-on treatment in hypertensives?
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Arteries; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Diastole; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrroles; Stroke Volume; Systole; Treatment Outcome; Vascular Resistance | 2003 |
[Statin soon to become standard addition to antihypertensive therapy? Better prevention of coronary heart disease for hypertensive patients].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2003 |
[Following the ASCOT Study. A statin for every hypertensive patient?].
Topics: Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Treatment Outcome | 2003 |
[Clinical study of the month. Premature interruption of ASCOT and CARDS clinical trials of cardiovascular prevention with atorvastatin in patients with arterial hypertension or diabetes mellitus: compromise between ethics and statistics in evidence-based
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Diabetes Complications; Ethics, Research; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Ireland; Pyrroles; Risk Factors; Scandinavian and Nordic Countries; United Kingdom | 2003 |
Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman.
Topics: Adult; Anxiety Disorders; Apgar Score; Atorvastatin; Chronic Disease; Diabetes Complications; Epilepsy; Female; Gliclazide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Infant, Newborn; Obesity, Morbid; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pyrroles; Rosiglitazone; Thiazolidinediones | 2004 |
[Cost-effectiveness of atorvastatin for the prevention of coronary disease. An analysis of the ASCOT study].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Cost-Benefit Analysis; Female; Germany; Health Care Costs; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2004 |
Amlodipine/atorvastatin (Caduet).
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Pyrroles | 2004 |
Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress.
Topics: Animals; Aorta; Atorvastatin; Down-Regulation; Endothelium, Vascular; Heart Ventricles; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; In Vitro Techniques; Male; Myocardial Reperfusion Injury; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Organ Size; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; Sodium, Dietary | 2004 |
[Statins and hypertension].
Topics: Anticholesteremic Agents; Atorvastatin; Drug Costs; Heptanoic Acids; Humans; Hypertension; Pyrroles; Stroke | 2004 |
Statin-associated exacerbation of myasthenia gravis.
Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone | 2004 |
Cyclical Cushing's disease causing recurrent oedema and knee effusions.
Topics: Adult; Antihypertensive Agents; Atorvastatin; Diuretics; Drug Therapy, Combination; Edema; Enalapril; Follow-Up Studies; Heptanoic Acids; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Knee; Male; Pituitary ACTH Hypersecretion; Pyrroles; Sodium Chloride Symporter Inhibitors | 2005 |
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Kidney; Kidney Glomerulus; Linear Models; Microscopy, Electron; Obesity; Pyrroles; Quinapril; Rats; Rats, Zucker; Staining and Labeling; Tetrahydroisoquinolines | 2005 |
Effects of atorvastatin on blood-brain barrier permeability during L-NAME hypertension followed by angiotensin-II in rats.
Topics: Angiotensin II; Animals; Atorvastatin; Blood-Brain Barrier; Heptanoic Acids; Hypertension; Male; NG-Nitroarginine Methyl Ester; Permeability; Pyrroles; Rats; Rats, Wistar | 2005 |
The effects of quinapril and atorvastatin on artery structure and function in adult spontaneously hypertensive rats.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Apoptosis; Arteries; Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Electric Stimulation; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; In Situ Nick-End Labeling; In Vitro Techniques; Male; Mesenteric Arteries; Microscopy, Confocal; Nitroprusside; Norepinephrine; Pyrroles; Quinapril; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrahydroisoquinolines; Time Factors; Vasoconstriction; Vasoconstrictor Agents; Vasodilator Agents | 2005 |
[ASCOT-BPLA Study raises new questions regarding: which is the best initial antihypertensive drug?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Doxazosin; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Sodium Chloride Symporter Inhibitors; Treatment Outcome | 2005 |
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorv
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Combinations; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Lipid Metabolism; Multicenter Studies as Topic; Pyrroles; Surveys and Questionnaires; Tablets | 2006 |
Statins for high-risk patients without heart disease or high cholesterol.
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke | 2006 |
Reduction in cardiovascular events with atorvastatin in type 2 diabetes.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2006 |
Medication costs as a primary cause of nonadherence in the elderly.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Prescriptions; Drugs, Generic; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Metformin; Metoprolol; Patient Compliance; Pharmacists; Pyrroles; Self Administration | 2006 |
Atorvastatin prevented and partially reversed adrenocorticotropic hormone-induced hypertension in the rat.
Topics: Adrenocorticotropic Hormone; Animals; Atorvastatin; Blood Pressure; Body Weight; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Nitric Oxide; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides | 2006 |
Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.
Topics: Analysis of Variance; Animals; Atorvastatin; Biomarkers; Blood Pressure; Body Weight; Dexamethasone; Disease Models, Animal; Down-Regulation; Glucocorticoids; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Nitrates; Nitric Oxide Synthase Type III; Nitrites; Organ Size; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Thymus Gland | 2006 |
Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis.
Topics: Albuminuria; Analysis of Variance; Animals; Atorvastatin; Blood Pressure; Caveolin 1; Glomerular Filtration Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Diseases; Kidney Glomerulus; Male; Models, Animal; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pyrroles; Rats; Rats, Wistar; rhoA GTP-Binding Protein; Vascular Endothelial Growth Factor A | 2006 |
Statins and cerebral vasomotor reactivity: implications for a new therapy?
Topics: Adult; Animals; Arginine; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials, Phase II as Topic; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Intracranial Aneurysm; Mice; Middle Cerebral Artery; Nitric Oxide; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Stroke; Subarachnoid Hemorrhage; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasomotor System; Vasospasm, Intracranial | 2006 |
Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.
Topics: Animals; Antioxidants; Aorta; Atorvastatin; Dexamethasone; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hypertension; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; RNA, Messenger; Vasoconstriction; Vasodilation | 2006 |
Possible role of exogenous cAMP to improve vascular endothelial dysfunction in hypertensive rats.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Aorta; Atorvastatin; Blood Pressure; Cyclic AMP; Drug Administration Schedule; Endothelium, Vascular; Heptanoic Acids; Hypertension; Male; NADPH Oxidases; Nitrates; Nitric Oxide Synthase Type III; Nitrites; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Thiobarbituric Acid Reactive Substances; Vasodilation | 2006 |
[Effects of atorvastatin in N-terminal pro-brain natriuretic peptide plasma levels in hypercholesterolemic patients with or without hypertension].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Pyrroles | 2006 |
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Family Practice; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Middle Aged; Patient Satisfaction; Pyrroles; Simvastatin; Tetrazoles; Treatment Outcome | 2007 |
Effect of demethylasterriquinone b1 in hypertension associated vascular endothelial dysfunction.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Microscopy, Electron; Muscle Relaxation; Muscle, Smooth, Vascular; NADPH Oxidases; Nitrates; Nitric Oxide Synthase Type III; Nitrites; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Superoxides; Thiobarbituric Acid Reactive Substances | 2007 |
[Effect of atorvastatin on left ventricular remodeling in spontaneously hypertensive rats].
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Blood Pressure; Heptanoic Acids; Hydroxyproline; Hypertension; Lipids; Male; Myocardium; Proliferating Cell Nuclear Antigen; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Up-Regulation; Ventricular Remodeling | 2007 |
Upregulation of nitric oxide, inhibition of oxidative stress, and antihypertensive effects of statins.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Nitric Oxide; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Dahl; Reactive Oxygen Species; Up-Regulation; Vasoconstriction | 2007 |
Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Arginine; Atorvastatin; Brain; Cerebral Arteries; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipid Metabolism; Male; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Inbred SHR; Stroke; Survival Rate; Time; Time Factors; Treatment Outcome | 2007 |
[Effects of atorvastatin on endothelium protection in spontaneously hypertensive rats].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Endothelium, Vascular; Heptanoic Acids; Hypertension; Lipids; Male; Nitric Oxide; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; von Willebrand Factor | 2007 |
Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cholesterol; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Losartan; Male; Pyrroles; Retrospective Studies; Simvastatin; Tetrazoles; Therapeutic Equivalency; Treatment Outcome | 2008 |
Systemic evaluation of gene expression changes in major target organs induced by atorvastatin.
Topics: Animals; Atorvastatin; Blood Pressure; Brain; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulation; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney; Lipids; Male; Myocardium; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reproducibility of Results; RNA, Messenger; Time Factors | 2008 |
Statin treatment improves cerebral more than systemic endothelial dysfunction in patients with arterial hypertension.
Topics: Arginine; Atorvastatin; Blood Circulation; Cerebrovascular Circulation; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Ultrasonography, Doppler, Transcranial | 2008 |
Specific amelioration of cerebral endothelial dysfunction in hypertensive patients treated with atorvastatin.
Topics: Animals; Atorvastatin; Cerebrovascular Circulation; Cerebrovascular Disorders; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles | 2008 |
Coronary revascularization and aggressive lipid lowering.
Topics: Aspirin; Atorvastatin; Coronary Stenosis; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Metoprolol; Middle Aged; Myocardial Revascularization; Plasminogen Activators; Pyrroles; Risk Factors | 1999 |
HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.
Topics: Angiotensin Receptor Antagonists; Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Blood Pressure; Culture Techniques; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipids; Male; NADPH Oxidases; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Vasoconstriction; Vasodilation | 2001 |
Simvastatin and atorvastatin enhance hypotensive effect of diltiazem in rats.
Topics: Animals; Antihypertensive Agents; Atorvastatin; Blood Pressure; Diltiazem; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley | 2001 |
Cellular antioxidant effects of atorvastatin in vitro and in vivo.
Topics: Animals; Antioxidants; Atorvastatin; Catalase; Cattle; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Muscle, Smooth, Vascular; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidases; Pyrroles; Rats; Rats, Inbred SHR; Reactive Oxygen Species; RNA, Messenger; Up-Regulation | 2002 |